Bharat Parenterals Ltd
Bharat Parenterals Ltd. is a Gujarat based pharmaceutical company producing general and B-lactum group of drugs as well as antiretroviral drugs. [1]
- Market Cap ₹ 982 Cr.
- Current Price ₹ 1,701
- High / Low ₹ 1,702 / 321
- Stock P/E 34.1
- Book Value ₹ 357
- Dividend Yield 0.04 %
- ROCE 13.7 %
- ROE 11.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 9.84% over past five years.
- Company has a low return on equity of 13.2% over last 3 years.
- Earnings include an other income of Rs.15.7 Cr.
- Dividend payout has been low at 0.59% of profits over last 3 years
- Company has high debtors of 188 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
81 | 95 | 114 | 119 | 125 | 111 | 136 | 220 | 226 | 204 | 212 | 218 | 239 | |
69 | 86 | 102 | 108 | 114 | 104 | 123 | 189 | 196 | 179 | 183 | 196 | 208 | |
Operating Profit | 12 | 9 | 12 | 11 | 10 | 7 | 13 | 30 | 30 | 25 | 29 | 22 | 31 |
OPM % | 14% | 10% | 10% | 9% | 8% | 6% | 10% | 14% | 13% | 12% | 14% | 10% | 13% |
0 | 3 | -1 | 4 | 5 | 8 | 7 | 13 | 11 | 9 | 7 | 19 | 16 | |
Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 |
Depreciation | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 6 |
Profit before tax | 8 | 8 | 6 | 9 | 9 | 8 | 14 | 36 | 35 | 27 | 28 | 32 | 38 |
Tax % | 17% | 10% | -3% | 15% | 31% | 7% | 27% | 37% | 25% | 25% | 25% | 24% | |
6 | 7 | 7 | 7 | 6 | 7 | 10 | 23 | 26 | 20 | 21 | 24 | 29 | |
EPS in Rs | 11.26 | 12.93 | 11.43 | 12.98 | 11.26 | 12.88 | 17.63 | 39.39 | 45.90 | 35.27 | 36.89 | 42.15 | 49.89 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | -1% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 14% |
3 Years: | -9% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 54% |
3 Years: | 63% |
1 Year: | 418% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 23 | 30 | 37 | 44 | 51 | 58 | 69 | 91 | 117 | 138 | 160 | 185 | 200 |
5 | 14 | 21 | 16 | 19 | 6 | 9 | 5 | 1 | 12 | 15 | 46 | 59 | |
24 | 26 | 37 | 50 | 44 | 40 | 50 | 60 | 68 | 40 | 37 | 71 | 87 | |
Total Liabilities | 58 | 76 | 101 | 116 | 120 | 111 | 133 | 161 | 192 | 196 | 218 | 308 | 353 |
20 | 23 | 29 | 29 | 35 | 31 | 34 | 35 | 33 | 45 | 41 | 36 | 39 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 12 | 0 | 1 | 0 | 0 |
Investments | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 42 | 16 | 38 | 43 |
37 | 53 | 72 | 87 | 85 | 79 | 99 | 123 | 147 | 110 | 160 | 233 | 270 | |
Total Assets | 58 | 76 | 101 | 116 | 120 | 111 | 133 | 161 | 192 | 196 | 218 | 308 | 353 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2 | 5 | 0 | -2 | 6 | 20 | 14 | 22 | -22 | -12 | |||
-5 | -8 | 0 | -2 | -8 | -9 | -13 | -41 | 22 | -14 | |||
7 | 6 | 0 | -8 | 4 | -4 | -3 | 11 | 2 | 29 | |||
Net Cash Flow | 1 | 2 | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 76 | 126 | 179 | 129 | 144 | 158 | 109 | 132 | 122 | 126 | 188 |
Inventory Days | 55 | 111 | 70 | 55 | 62 | 69 | 60 | 55 | 69 | 61 | 56 | 100 |
Days Payable | 121 | 95 | 119 | 188 | 171 | 167 | 110 | 82 | 106 | 71 | 60 | 127 |
Cash Conversion Cycle | 21 | 91 | 77 | 47 | 20 | 46 | 108 | 82 | 95 | 111 | 122 | 161 |
Working Capital Days | 29 | 74 | 67 | 72 | 45 | 65 | 95 | 81 | 97 | 118 | 159 | 163 |
ROCE % | 29% | 21% | 18% | 17% | 15% | 12% | 19% | 40% | 32% | 20% | 18% | 14% |
Documents
Announcements
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 10h
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 11h
- Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 (1) (D) Of SEBI LODR Provision For Preferential Allotment Of Equity Shares 12h
- Compliance Certificate For The Year Ended On 31St March, 2024 Certifying That All Certificates Are Issued Within 30Days Of Date Of Lodgment Of Transfer, Transimission, Sub-Division, Cosolidation Etc 18 Apr
-
Compliances-Compliance Certificate For The Period Ended March, 2024.
13 Apr - Compliance Certificate for the year ended on 31st March, 2024 related to share transfer facility.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2003
from bse
-
Financial Year 2002
from bse
-
Financial Year 1999
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
Product Portfolio
The Co has a portfolio of over 500 formulations. It produces pharmaceuticals across categories such as B-LACTAM Antibiotics, Anti Retroviral, Cephalosporins Antibiotics, Antiprotozoal / Anthelmintic Respiratory, Antiallergic, Cleansing Agents /Skin Infections, Cardiovascular System, Anti Diabitic, Anti Fungal etc. [1]